With the widespread clinical application of the subcutaneous injection of PD-L1 antibody drug 恩维达® (Envafolimab)in tumor treatment, good news of its academic progress has been continuously reported.

Recently, a clinical study of a PD-L1 inhibitor combined with chemotherapy and targeted therapy (Envafolimab and Durvalumab) achieved a median progression-free survival of 11.29 months and a median overall survival of 14.8 months in 43 patients with advanced biliary tract cancer.

Professor Kuang Ming from The First Affiliated Hospital, Sun Yat-sen University, the lead researcher of the study, will deliver an oral presentation at the 33rd Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL) on March 30, 2024.

In March 2024, Envafolimab was included in the 2024 edition of the “Chinese Expert Consensus on the Use of Immune Checkpoint Inhibitors in Perioperative Treatment of Advanced Gastric Cancer” published by the Gastric Cancer Committee of the Chinese Anti-Cancer Association.

So far, Envafolimab has been recommended in 15 latest authoritative clinical guidelines and consensus recommendations both in China and abroad.